Retrieve available abstracts of 46 articles: HTML format
Single Articles
June 2025
SHAMSEDDINE A, Turfa R, Chehade L, Zeidan YH, et al Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced
microsatellite stable rectal adenocarcinoma: The Averectal study.
Eur J Cancer. 2025;222:115428. PubMedAbstract available
May 2025
HAFLIGER E, Nili-Asgari R, Netter J, Taieb J, et al Case report of two fatal cerebral hemorrhages in patients with metastatic
colorectal cancer treated with Fruquintinib.
Eur J Cancer. 2025 May 19:115517. doi: 10.1016/j.ejca.2025.115517. PubMed
April 2025
MORETTO R, Rossini D, Polito MG, Antoniotti C, et al The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in
combination with bevacizumab affects prognosis of metastatic colorectal cancer
patients: A pooled analysis of TRIBE and TRIBE2 studies.
Eur J Cancer. 2025;222:115470. PubMedAbstract available
PIZZAMIGLIO M, Soulabaille A, Lahlou W, Pilla L, et al Advances and challenges in targeted therapies for HER2-amplified colorectal
cancer.
Eur J Cancer. 2025;222:115471. PubMedAbstract available
NORONHA MM, Costa Almeida LF, Cappellaro AP, Silva LFLD, et al Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis
of randomized controlled trials.
Eur J Cancer. 2025;222:115476. PubMedAbstract available
JORGENSEN SF, Njor SH, Nevala A, Palsson B, et al Nordic colorectal cancer screening programmes: A comparison of organization,
operation, and quality indicators.
Eur J Cancer. 2025;222:115444. PubMedAbstract available
WEISS L, Stintzing S, Stahler A, Benedikt Westphalen C, et al Molecular hyperselection for optimal choice of first-line targeted therapy
independent of primary tumor sidedness: An exploratory analysis of the randomized
FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
Eur J Cancer. 2025;221:115399. PubMedAbstract available
March 2025
HOLCH JW, Ohnmacht AJ, Stintzing S, Heinrich K, et al FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal
cancer: Refining first-line treatment selection by combining clinical parameters:
A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO
KRK0306.
Eur J Cancer. 2025;220:115388. PubMedAbstract available
MORETTO R, Boccaccio C, Landi M, Masi G, et al Total neoadjuvant treatment, non-operative management and radiotherapy-free
strategies: New approaches for the management of proficient mismatch
repair/microsatellite stable locally advanced rectal cancer. A narrative review
and evidence-based algorit
Eur J Cancer. 2025;218:115261. PubMedAbstract available
CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al Are all mismatch repair deficient endometrial cancers created equal? A large,
retrospective, tertiary center experience.
Eur J Cancer. 2025;220:115344. PubMedAbstract available
February 2025
POUMEAUD F, Valentin T, Fares N, Segier B, et al Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic
soft-tissue sarcomas and are sensitive to immunotherapy.
Eur J Cancer. 2025;216:115196. PubMedAbstract available
QIU X, Zhou J, Qiu H, Shen Z, et al A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical
complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal
endoscopic microsurgery --A multicenter prospective case-control clinical trial
by MONT-R.
Eur J Cancer. 2025;216:115156. PubMedAbstract available
January 2025
SOBRERO A, Dasari A, Aquino J, Lonardi S, et al Health-related quality of life associated with fruquintinib in patients with
metastatic colorectal cancer: Results from the FRESCO-2 study.
Eur J Cancer. 2025;218:115268. PubMedAbstract available
WANG DS, Pat Fong W, Wen L, Cai YY, et al Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic
arterial infusion of floxuridine in patients following colorectal cancer liver
metastasectomy (HARVEST trial): A randomized controlled trial.
Eur J Cancer. 2025;214:115154. PubMedAbstract available
December 2024
CARBONE F, Spinelli A, Ciardiello D, Realis Luc M, et al Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic
review and meta-analysis.
Eur J Cancer. 2024;215:115172. PubMedAbstract available
TOUGERON D, Bibeau F, Chibaudel B, Kim S, et al Resection of colorectal liver metastases with second-line aflibercept plus
FOLFIRI: Results from the RESECTION prospective French cohort.
Eur J Cancer. 2024;213:115082. PubMedAbstract available
November 2024
HIRANO H, Kataoka K, Yamaguchi T, Wagner AD, et al Sex differences in toxicities and survival outcomes among Japanese patients with
Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A
pooled analysis of 4 randomized controlled trials (JCOG2310A).
Eur J Cancer. 2024;214:115139. PubMedAbstract available
DUNN C, Shapiro J, Lee M, Wong R, et al Measuring quality in the care of metastatic colorectal cancer utilising available
registry data: A modified Delphi study.
Eur J Cancer. 2024;214:115142. PubMedAbstract available
XIAO A, Li X, Wang C, Ye J, et al Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory
microsatellite stable non-liver metastatic colorectal cancer: A phase I
nonrandomized clinical trial.
Eur J Cancer. 2024;213:115111. PubMedAbstract available
SUN L, Xu Y, Chen N, Zhang C, et al Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant
chemotherapy for patients with stage II and III colon cancer: A randomized
clinical trial.
Eur J Cancer. 2024;213:115109. PubMedAbstract available
FRYDENDAHL A, Nors J, Rasmussen MH, Henriksen TV, et al Detection of circulating tumor DNA by tumor-informed whole-genome sequencing
enables prediction of recurrence in stage III colorectal cancer patients.
Eur J Cancer. 2024;211:114314. PubMedAbstract available
October 2024
STINTZING S, Yoshino T Response to letter re: A meta-analysis of efficacy and safety data from
head-to-head first-line trials of epidermal growth factor receptor inhibitors
versus bevacizumab in adult patients with RAS wild-type metastatic colorectal
cancer by sidedness.
Eur J Cancer. 2024;210:114298. PubMed
FOKAS E, Williams H, Diefenhardt M, Lin S, et al Chemoradiotherapy plus induction or consolidation chemotherapy as total
neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the
CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.
Eur J Cancer. 2024;210:114291. PubMedAbstract available
September 2024
SMABERS LP, Huismans MA, van Nieuwenhuijzen N, Minnema MC, et al Efficacy and safety in early-phase clinical trials for refractory colorectal
cancer: A meta-analysis.
Eur J Cancer. 2024;212:115059. PubMedAbstract available
MARGALIT O, Stemmer A, Chapin WJ, Shacham-Shmueli E, et al Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients.
Eur J Cancer. 2024;212:114336. PubMedAbstract available
BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al Estimating cure and risk of death from other causes of cancer patients:
EUROCARE-6 data on head & neck, colorectal, and breast cancers.
Eur J Cancer. 2024;208:114187. PubMedAbstract available
August 2024
AMBROSINI M, Tougeron D, Modest D, Guimbaud R, et al BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E
mutated and deficient mismatch repair or microsatellite instability high
metastatic colorectal cancer.
Eur J Cancer. 2024;210:114290. PubMedAbstract available
XIE Z, Lin H, Huang Y, Wang X, et al BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with
adverse outcomes in colorectal cancer.
Eur J Cancer. 2024;210:114278. PubMedAbstract available
ZHANG P, Han Y, Cai Z, Cao D, et al Letter Re: A meta-analysis of efficacy and safety data from head-to-head
first-line trials of epidermal growth factor receptor inhibitors versus
bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by
sidedness.
Eur J Cancer. 2024 Aug 6:114266. doi: 10.1016/j.ejca.2024.114266. PubMed
MICHIEL ZEEUW J, Wesdorp NJ, Ali M, Bakker AJJ, et al Prognostic value of total tumor volume in patients with colorectal liver
metastases: A secondary analysis of the randomized CAIRO5 trial with external
cohort validation.
Eur J Cancer. 2024;207:114185. PubMedAbstract available
July 2024
FRANKEN IA, van der Baan FH, Vink GR, May AM, et al Survival and patient-reported outcomes of real-world high-risk stage II and stage
III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3
months.
Eur J Cancer. 2024;208:114207. PubMedAbstract available
June 2024
MERCIER L, Delaye M, Fuerea A, Ducreux M, et al Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer.
Eur J Cancer. 2024;208:114193. PubMed
ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al Exploring the biology of ctDNA release in colorectal cancer.
Eur J Cancer. 2024;207:114186. PubMedAbstract available
SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al Corrigendum to "Trends in incidence, treatment, and relative survival of
colorectal cancer in the Netherlands between 2000 and 2021'' Volume 205, July
2024, 114104.
Eur J Cancer. 2024 Jun 11:114155. doi: 10.1016/j.ejca.2024.114155. PubMed
COHEN R, Raeisi M, Chibaudel B, Shi Q, et al Prognostic value of liver metastases in colorectal cancer treated by systemic
therapy: An ARCAD pooled analysis.
Eur J Cancer. 2024;207:114160. PubMedAbstract available
ZWART WH, Temmink SJD, Hospers GAP, Marijnen CAM, et al Oncological outcomes after a pathological complete response following total
neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal
cancer in the RAPIDO trial.
Eur J Cancer. 2024;204:114044. PubMedAbstract available
May 2024
CHEN C, Feng YS, Wang Z, Gupta M, et al Organ-specific tumor dynamics predict survival of patients with metastatic
colorectal cancer.
Eur J Cancer. 2024;207:114147. PubMedAbstract available
TAIEB J, Basile D, Seligmann J, Argiles G, et al Standardizing data collection in adjuvant colon cancer trials: A consensus
project from the IDEA and ACCENT international consortia and national experts.
Eur J Cancer. 2024;206:114118. PubMedAbstract available
SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al Trends in incidence, treatment, and relative survival of colorectal cancer in the
Netherlands between 2000 and 2021.
Eur J Cancer. 2024;205:114104. PubMedAbstract available
MOREAU M, Alouani E, Flecchia C, Falcoz A, et al A multicenter study evaluating efficacy of immune checkpoint inhibitors in
advanced non-colorectal digestive cancers with microsatellite instability.
Eur J Cancer. 2024;202:114033. PubMedAbstract available
VAN GEFFEN EGM, Langhout JMA, Hazen SJA, Sluckin TC, et al Evolution of clinical nature, treatment and survival of locally recurrent rectal
cancer: Comparative analysis of two national cross-sectional cohorts.
Eur J Cancer. 2024;202:114021. PubMedAbstract available
March 2024
TAKASHIMA A, Garcia-Alfonso P, Manneh R, Besen AA, et al Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine
as maintenance therapy in advanced colorectal cancer: The randomized phase 3
LYNK-003 study.
Eur J Cancer. 2024;205:114036. PubMedAbstract available
BARBE R, Belkouchi Y, Menu Y, Cohen R, et al Imaging-guided prognostic score-based approach to assess the benefits of
combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic
MSI-H colorectal cancer patients.
Eur J Cancer. 2024;202:114020. PubMedAbstract available
SPIEKMAN IAC, Zeverijn LJ, Geurts BS, Verkerk K, et al Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer:
Results from the drug rediscovery protocol (DRUP).
Eur J Cancer. 2024;202:113988. PubMedAbstract available
LI L Comment on: Despite multi-disciplinary team discussions the socioeconomic
disparities persist in the oncological treatment of non-metastasized colorectal
cancer.
Eur J Cancer. 2024;202:113982. PubMed
YOSHINO T, Hooda N, Younan D, Muro K, et al A meta-analysis of efficacy and safety data from head-to-head first-line trials
of epidermal growth factor receptor inhibitors versus bevacizumab in adult
patients with RAS wild-type metastatic colorectal cancer by sidedness.
Eur J Cancer. 2024;202:113975. PubMedAbstract available